7-Difluoromethyl-5,4′-dimethoxygenistein, a novel genistein derivative, has therapeutic effects on atherosclerosis in a rabbit model

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 5, 2009, Pages 412-420

  Zhao, Hong ^a   Li, Cheng ^a   Cao, Jian Guo ^a   Xiang, Hong Lin ^a   Yang, Hua Zhong ^a   You, Ji Liang ^a   Li, Cheng Long ^a   Fu, Xiao Hua ^a  

^a HUNAN NORMAL UNIVERSITY   (China)

Author keywords

4 dimethoxygenistein; 7 difluoromethyl 5; Atherosclerosis; Genistein; Therapeutic effect

Indexed keywords

7 DIFLUOROMETHYL 5,4' DIMETHOXYGENISTEIN; CHOLESTEROL; COLLAGEN; GENISTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTERY MUSCLE; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CONTROLLED STUDY; IN VIVO STUDY; LIPID PEROXIDATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THORACIC AORTA;

ANIMALS; AORTA, ABDOMINAL; AORTA, THORACIC; ATHEROSCLEROSIS; CHOLESTEROL; COLLAGEN; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GENISTEIN; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALE; PHYTOESTROGENS; RABBITS;

EID: 74349099104     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181bad280     Document Type: Article

References (48)

1. Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009;15:467-478.
2. Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the reversal of atherosclerosis with aggressive lipid lowering (REVERSAL) trial. Am J Cardiol. 2005;96:F61-F68.
3. Insull W Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med. 2009;122(Suppl 1): S3-S14.
4. Bybee KA, Lee JH, O#Keefe JH. Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Curr Med Res Opin. 2008;24:1217-1229.
5. Kinlay S, Schwartz GG, Olsson AG, et al; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004;110:386-391.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
7. Stein EA. Other therapies for reducing low-density lipoprotein cholesterol: medications in development. Endocrinol Metab Clin North Am. 2009;38:99-119.
8. Stein EA, Ballantyne CM, Windler E, et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of musclerelated side effects with other statins. Am J Cardiol. 2008;101:490-496.
9. Si H, Liu D. Phytochemical genistein in the regulation of vascular function: new insights. Curr Med Chem. 2007;14:2581-2589.
10. Yamaguchi M. Regulatory mechanism of food factors in bone metabolism and prevention of osteoporosis. Yakugaku Zasshi. 2006;126:1117-1137.
11. Duffy C, Perez K, Partridge A. Implications of phytoestrogen intake for breast cancer. CA Cancer J Clin. 2007;57:260-277.
12. Perabo FG, Von Löw EC, Ellinger J, et al. Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2008;11:6-12.
13. Adams MR, Golden DL, Williams JK, et al. Soy protein containing isoflavones reduces the size of atherosclerotic plaques without affecting coronary artery reactivity in adult male monkeys. J Nutr. 2005;135: 2852-2856.
14. Rimbach G, Boesch-Saadatmandi C, Frank J, et al. Dietary isoflavones in the prevention of cardiovascular disease-a molecular perspective. Food Chem Toxicol. 2008;46:1308-1319.
15. Setchell KD, Brown NM, Zimmer-Nechemias L, et al. Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am J Clin Nutr. 2002;76:447-453.
16. Rowland I, Faughnan M, Hoey L, et al. Bioavailability of phytooestrogens. Br J Nutr. 2003;89(Suppl 1):S45-S58.
17. Fu XH, Wang L, Zhao H, et al. Synthesis of genistein derivatives and determination of their protective effects against vascular endothelial cell damages caused by hydrogen peroxide. Bioorg Med Chem Lett. 2008;18: 513-517.
18. Sugano M, Nakashima Y, Tasaki H, et al. Effects of diltiazem on suppression and regression of experimental atherosclerosis. Br J Exp Pathol. 1988;69:515-523.
19. Prasad K. Regression of hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Atherosclerosis. 2008;197:34-42.
20. Kockx MM, De Meyer GR, Buyssens N, et al. Cell composition, replication, and apoptosis in atherosclerotic plaques after 6 months of cholesterol withdrawal. Circ Res. 1998;83:378-387.
21. Metz S, Riedmüller K, Kinscherf R, et al. Possibilities of regression in arteriosclerosis. Z Gerontol Geriatr. 2001;34:466-469.
22. Prasad K, Lee P. Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis. 2007;192:313-322.
23. Prasad K, Mantha SV, Muir AD, et al. Reduction of hypercholesterolemic atherosclerosis by CDC-flaxseed with very low alpha-linolenic acid. Atherosclerosis. 1998;136:367-375.
24. Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation. 1999;99:1355-1362.
25. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995; 91:2488-2496.
26. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
27. Puddu GM, Cravero E, Arnone G, et al. Molecular aspects of atherogenesis: new insights and unsolved questions. J Biomed Sci. 2005;12:839-853.
28. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
29. Mügge A. The role of reactive oxygen species in atherosclerosis. Z Kardiol. 1998;87:851-864.
30. Pearson TA, Mensah GA, Alexander RW, et al; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
31. Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332:635-641.
32. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
33. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
34. Chen YH, Lin SJ, Chen YL, et al. Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules. Cardiovasc Hematol Disord Drug Targets. 2006;6: 279-304.
35. Wang L, Zheng X, Xiang HL, et al. 7-Difluoromethyl-5,4#- dimethoxygenistein inhibits oxidative stress induced adhesion between endothelial cells and monocytes via NF-kappaB. Eur J Pharmacol. 2009;605:31-35.
36. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992; 326:310-318.
37. Gotlieb AI. Atherosclerosis and acute coronary syndromes. Cardiovasc Pathol. 2005;14:181-184.
38. Leskinen MJ, Kovanen PT, Lindstedt KA. Regulation of smooth muscle cell growth, function and death in vitro by activated mast cells-a potential mechanism for the weakening and rupture of atherosclerotic plaques. Biochem Pharmacol. 2003;66:1493-1498.
39. Virmani R, Burke AP, Kolodgie FD, et al. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol. 2002;15: 439-446.
40. van der Wal AC, Becker AE. Atherosclerotic plaque rupture-pathologic basis of plaque stability and instability. Cardiovasc Res. 1999;41: 334-344.
41. Sukhova GK, Schönbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and-3 in vulnerable human atheromatous plaques. Circulation. 1999;99:2503-2509.
42. Erl W. Statin-induced vascular smooth muscle cell apoptosis: a possible role in the prevention of restenosis? Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:135-144.
43. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 2001;103:993-999.
44. Ferri N, Colombo G, Ferrandi C, et al. Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation. Arterioscler Thromb Vasc Biol. 2007;27:1043-1049.
45. Altavilla D, Crisafulli A, Marini H, et al. Cardiovascular effects of the phytoestrogen genistein. Curr Med Chem Cardiovasc Hematol Agents. 2004;2:179-186.
46. Liang HW, Qiu SF, Shen J, et al. Genistein attenuates oxidative stress and neuronal damage following transient global cerebral ischemia in rat hippocampus. Neurosci Lett. 2008;438:116-120.
47. Abazinge M, Jackson T, Yang Q, et al. In vitro and in vivo characterization of biodegradable enoxacin microspheres. Eur J Pharm Biopharm. 2000; 49:191-194.
48. Comte G, Daskiewicz JB, Bayet C, et al. C-Isoprenylation of flavonoids enhances binding affinity toward P-glycoprotein and modulation of cancer cell chemoresistance. J Med Chem. 2001;44:763-768.